Highlights

  • Collaboration revenue was $6.3 million for the three months ended June 30, 2026, and the net loss was $67,255 thousand.
  • Cash, cash equivalents and marketable securities were $457.4 million at June 30, 2026, with management projecting runway into 2028.
  • The initial public offering closed on March 2, 2026, with 25,000,000 shares sold and net proceeds of $369.3 million.
  • GB-0895 is being evaluated in pivotal Phase 3 trials for severe asthma, and no company products are approved for sale.

Generate Biomedicines (NASDAQ:GENB) shares were trading at USD 15.00 on October 28, 2026, up 13.55%, with a relative volume at time of 6.52. The clinical-stage company closed its initial public offering on March 2, 2026, and filed its quarterly report on Form 10-Q for the period ended June 30, 2026 on August 6, 2026, which describes its Phase 3 program and cash position.

Generate Biomedicines, Inc. is incorporated in Delaware and lists its principal executive offices in Somerville, Massachusetts. It describes itself as a clinical-stage generative biology company that applies computational design and laboratory automation through The Generate Platform to engineer therapeutic proteins. Its programs include GB-0895, GB-4362 and GB-5267, along with preclinical programs in immunology and oncology. The company has collaborations with Novartis and Amgen. Its fiscal year ends December 31, and its common stock is listed on the Nasdaq Global Select Market. It has no products approved for sale.

Second Quarter 2026 Results

Collaboration revenue was $6.3 million for the three months ended June 30, 2026, compared with $10.1 million for the same period of 2025.

Research and development expenses were $64.3 million, compared with $59.7 million. External costs for GB-0895 were $20.5 million, compared with $13.3 million. General and administrative expenses were $13.6 million, compared with $10.5 million. Loss from operations was $71,614 thousand, compared with $60,150 thousand.

Net loss was $67,255 thousand for the quarter, compared with $56,742 thousand a year earlier. For the six months ended June 30, 2026, the net loss was $129.0 million, compared with $101.1 million, and collaboration revenue was $13.5 million, compared with $18.9 million. The accumulated deficit was $805.0 million at June 30, 2026.

Cash, Financing and Capital

Cash, cash equivalents and marketable securities were $457.4 million at June 30, 2026. Management said, based on its current operating plan, that these amounts will fund operations into the first half of 2028, and that it expects to require additional capital for long-term operations.

Net cash used in operating activities was $138,332 thousand for the six months ended June 30, 2026, compared with $101,929 thousand. Net cash provided by financing activities was $378.3 million, which the filing attributes primarily to proceeds from the issuance of common stock.

The company closed its initial public offering on March 2, 2026, issuing and selling 25,000,000 shares of common stock at a public offering price of $16.00, for net proceeds of $369.3 million. The filing states that the company had concluded there was going concern doubt as of December 31, 2025, and that the offering alleviated it. On February 26, 2026, the company acquired all of the outstanding capital stock of Pioneering Medicines 02, Inc., which ended the non-controlling interest.

Pipeline and Outlook

GB-0895 is an investigational long-acting anti-TSLP monoclonal antibody being evaluated in pivotal Phase 3 clinical trials for severe asthma. The company said its global Phase 3 trial in severe asthma commenced in the first quarter of 2026. GB-4362 is in a Phase 1 clinical trial, where the company has activated sites and dosed initial patients. GB-5267 is recruiting, and the company said the first patient is expected to be dosed in 2026.

The company has not given revenue or earnings guidance. It said it has not generated revenue from product sales, does not expect product revenue for the next several years, if at all, and expects to continue to incur losses. It also said it will need additional funding, which may not be available on acceptable terms, or at all.